SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.
ALFQ
B.1.1.7
B.1.351
COVID-19
P.1
SARS-CoV-1
SARS-CoV-2
betacoronaviruses
ferritin nanoparticle
neutralizing antibodies
receptor-binding domain
spike
variants of concern
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
21 12 2021
21 12 2021
Historique:
received:
17
05
2021
revised:
19
08
2021
accepted:
29
11
2021
pubmed:
18
12
2021
medline:
18
12
2021
entrez:
17
12
2021
Statut:
ppublish
Résumé
The need for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) next-generation vaccines has been highlighted by the rise of variants of concern (VoCs) and the long-term threat of emerging coronaviruses. Here, we design and characterize four categories of engineered nanoparticle immunogens that recapitulate the structural and antigenic properties of the prefusion SARS-CoV-2 spike (S), S1, and receptor-binding domain (RBD). These immunogens induce robust S binding, ACE2 inhibition, and authentic and pseudovirus neutralizing antibodies against SARS-CoV-2. A spike-ferritin nanoparticle (SpFN) vaccine elicits neutralizing titers (ID
Identifiants
pubmed: 34919799
pii: S2211-1247(21)01639-9
doi: 10.1016/j.celrep.2021.110143
pmc: PMC8651551
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110143Subventions
Organisme : NIAID NIH HHS
ID : R01 AI157155
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of interests M.G.J. and K.M. are named as inventors on international patent application WO/2021/178971 A1 entitled “Vaccines against SARS-CoV-2 and other coronaviruses.” M.G.J. is named as an inventor on international patent application WO/2018/081318 and U.S. patent 10,960,070 entitled “Prefusion coronavirus spike proteins and their use.” Z.B. is named as an inventor on U.S. patent 10,434,167 entitled “Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin.” Z.B. and G.R.M. are named as inventors on U.S. patent application 16/607,917 entitled “Compositions and methods for vaccine delivery.” M.S.D. is a consultant for Inbios, Vir Biotechnology, Fortress Biotech, and Carnival Corporation and on the scientific advisory boards of Moderna and Immunome. The Diamond laboratory has received funding support from sponsored research agreements from Moderna, Vir Biotechnology, Kaleido, and Emergent BioSolutions. S.R., P.M.M., and M.T.E. are employees of AstraZeneca and currently hold AstraZeneca stock or stock options. Z.B. is currently employed at Pfizer.
Références
PLoS Pathog. 2020 Sep 3;16(9):e1008764
pubmed: 32881968
PLoS Med. 2006 Jul;3(7):e237
pubmed: 16796401
Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5
pubmed: 32735849
Pathog Immun. 2019 Dec 11;4(2):294-323
pubmed: 31893251
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
Curr Infect Dis Rep. 2017 Mar;19(3):14
pubmed: 28275932
Nat Med. 2015 Dec;21(12):1508-13
pubmed: 26552008
Cell. 2015 Aug 27;162(5):1090-100
pubmed: 26279189
Protein Sci. 2018 Jan;27(1):14-25
pubmed: 28710774
JCI Insight. 2020 May 21;5(10):
pubmed: 32434990
Emerg Microbes Infect. 2020 Dec;9(1):382-385
pubmed: 32065055
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Nature. 2021 Aug;596(7872):417-422
pubmed: 34192737
NPJ Vaccines. 2021 Dec 13;6(1):151
pubmed: 34903722
Science. 2021 Aug 13;373(6556):
pubmed: 34210892
Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
Cell. 2020 Nov 25;183(5):1367-1382.e17
pubmed: 33160446
Cell. 2020 Jul 9;182(1):73-84.e16
pubmed: 32425270
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Cell. 2021 Mar 4;184(5):1188-1200.e19
pubmed: 33577765
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
Proc Natl Acad Sci U S A. 2021 Sep 21;118(38):
pubmed: 34470866
Elife. 2018 Mar 07;7:
pubmed: 29513216
J Struct Biol. 2015 Nov;192(2):216-21
pubmed: 26278980
Nat Methods. 2017 Mar;14(3):290-296
pubmed: 28165473
Science. 2021 Feb 12;371(6530):735-741
pubmed: 33436524
N Engl J Med. 2021 Jun 3;384(22):2161-2163
pubmed: 33826816
BMC Immunol. 2011 May 27;12:33
pubmed: 21619655
ACS Cent Sci. 2021 Jan 27;7(1):183-199
pubmed: 33527087
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Vaccine. 2018 Feb 1;36(6):906-914
pubmed: 29269157
Viruses. 2019 Mar 02;11(3):
pubmed: 30832356
Nat Commun. 2015 Jul 28;6:7712
pubmed: 26218507
Front Immunol. 2018 Oct 04;9:2224
pubmed: 30337923
Science. 2021 Feb 19;371(6531):823-829
pubmed: 33495307
Nature. 2021 Jun;594(7862):253-258
pubmed: 33873199
N Engl J Med. 2015 May 28;372(22):2087-96
pubmed: 25916341
Science. 2020 Oct 9;370(6513):203-208
pubmed: 32817270
Cell Host Microbe. 2021 May 12;29(5):819-833.e7
pubmed: 33789084
Cell. 2021 Feb 4;184(3):628-642.e10
pubmed: 33476549
Cell. 2020 May 28;181(5):1004-1015.e15
pubmed: 32375025
BMC Bioinformatics. 2006 Mar 09;7:123
pubmed: 16526949
Cell. 2019 Mar 7;176(6):1420-1431.e17
pubmed: 30849373
J Clin Invest. 2006 May;116(5):1167-73
pubmed: 16670757
EBioMedicine. 2021 Jan;63:103197
pubmed: 33422991
Epidemiol Rev. 2019 Jan 31;41(1):28-33
pubmed: 31673694
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Zootaxa. 2016 Oct 11;4174(1):410-423
pubmed: 27811808
Science. 2020 Nov 27;370(6520):1089-1094
pubmed: 33082295
Elife. 2020 Aug 04;9:
pubmed: 32748788
Nat Immunol. 2019 Mar;20(3):362-372
pubmed: 30742080
Nat Struct Mol Biol. 2021 Jun;28(6):478-486
pubmed: 33981021
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
J Struct Biol. 2005 Oct;152(1):36-51
pubmed: 16182563
Proc Natl Acad Sci U S A. 2020 Feb 11;117(6):3114-3122
pubmed: 31988134
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Immunity. 2021 Feb 9;54(2):324-339.e8
pubmed: 33453152
Science. 2019 Aug 2;365(6452):505-509
pubmed: 31371616
Cell Mol Immunol. 2021 Mar;18(3):749-751
pubmed: 33580169
Acta Crystallogr D Struct Biol. 2019 Oct 1;75(Pt 10):861-877
pubmed: 31588918
PLoS One. 2016 Jul 27;11(7):e0159709
pubmed: 27463224
Sci Transl Med. 2021 Mar 3;13(583):
pubmed: 33658355
Am J Pathol. 2020 Aug;190(8):1680-1690
pubmed: 32473109
Nature. 2013 Jul 4;499(7456):102-6
pubmed: 23698367
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
Emerg Infect Dis. 2020 Jan;26(1):166-168
pubmed: 31855530
JAMA. 2021 May 4;325(17):1784-1786
pubmed: 33720292
Vaccine. 2019 Jun 27;37(29):3793-3803
pubmed: 31151801
Risk Anal. 2019 Dec;39(12):2608-2624
pubmed: 31524301
Cell. 2019 Jul 25;178(3):567-584.e19
pubmed: 31348886
Retrovirology. 2015 Sep 26;12:82
pubmed: 26410741
Nat Struct Mol Biol. 2016 Sep;23(9):811-820
pubmed: 27478931
Science. 2013 Nov 1;342(6158):592-8
pubmed: 24179220
Nat Commun. 2016 Jun 28;7:12041
pubmed: 27349934
Nat Immunol. 2020 Nov;21(11):1327-1335
pubmed: 32839612
J Struct Biol. 2012 Dec;180(3):519-30
pubmed: 23000701